ORY-1001: Overcoming the Differentiation Block in AML
- PMID: 29533778
- DOI: 10.1016/j.ccell.2018.02.014
ORY-1001: Overcoming the Differentiation Block in AML
Abstract
In this issue of Cancer Cell, Maes and colleagues report in vitro and in vivo findings with ORY-1001-an oral, highly potent and selective covalent small-molecule inhibitor of lysine-specific demethylase 1 (LSD1)-in development for acute myeloid leukemia (AML), as well as correlative data from two AML patients receiving ORY-1001.
Copyright © 2018 Elsevier Inc. All rights reserved.
Comment on
-
ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia.Cancer Cell. 2018 Mar 12;33(3):495-511.e12. doi: 10.1016/j.ccell.2018.02.002. Epub 2018 Mar 1. Cancer Cell. 2018. PMID: 29502954
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical